Marco Valgimigli (Lugano, Switzerland) talks to Cardiovascular News about the latest findings from MASTER DAPT, a non-inferiority study that was designed to assess whether one month of DAPT preserved the benefit in relation to cardiovascular events, while mitigating bleeding outcomes, compared with longer treatment durations in high bleeding risk (HBR) patients following percutaneous coronary intervention (PCI).
Valgimigli talks about the importance of identifying HBR patients “up front” and notes that before MASTER DAPT there was “no randomised evidence informing us around optimal duration of dual antiplatelet therapy specifically in HBR patients”.
The study findings showed noninferiority of the abbreviated DAPT cohort compared to the standard DAPT cohort in terms of both net adverse clinical events (NACE) and major adverse cardiovascular events (MACE). However, adds Valgimigli, “we were able to prove superiority” with respect to the third co-primary endpoint—major or clinically relevant non-major bleeding.
These “clear-cut” findings indicate that one month DAPT is “becoming the standard of care” for patients undergoing PCR in and where a HBR feature is present. “We have shown that there is no penalty to pay with respect to ischaemic events by reducing DAPT duration down to one month”, concludes Valgimigli.
The findings were presented at the European Society of Cardiology’s 2021 congress (ESC 2021, 27–30 August, virtual). To learn more, visit: https://cardiovascularnews.com/esc2021-one-month-dual-antiplatelet-therapy-post-stent-implant-benefits-high-bleeding-risk-patients/
